Sonja Bak

Title: Sonja Bak - Innovator in Protein Conjugation

Introduction

Sonja Bak is a prominent inventor based in København NV, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of conjugated proteins. Her work focuses on enhancing the efficacy of therapeutic proteins, which has important implications for medical treatments.

Latest Patents

Sonja Bak holds a patent for "Conjugated proteins with prolonged in vivo efficacy." This invention relates to conjugated proteins, specifically blood coagulation factors. The patent details processes for preparing these proteins, which involve reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water-insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule. The resulting pharmaceutical compositions are designed for therapeutic use, particularly in treating diseases that require blood coagulation factors, such as hemophilia.

Career Highlights

Sonja Bak is associated with Novo Nordisk Healthcare AG, a leading company in the healthcare sector. Her work at Novo Nordisk has allowed her to focus on innovative solutions in protein therapy. With her expertise, she has contributed to advancements that improve patient outcomes in various medical conditions.

Collaborations

Throughout her career, Sonja has collaborated with notable colleagues, including Carsten Behrens and Patrick William Garibay. These collaborations have fostered a productive environment for research and development, leading to significant advancements in their field.

Conclusion

Sonja Bak is a trailblazer in the field of biotechnology, with her innovative work on conjugated proteins paving the way for improved therapeutic options. Her contributions are vital in the ongoing efforts to enhance treatment for patients with blood coagulation disorders.